|
|
|
|
|
|
|
|
Data from ICON7 will be submitted for presentation at an upcoming medical meeting, Genentech said.
The ICON7 study is sponsored by the Medical Research Council (MRC) in the UK, led by the MRC Clinical Trials Unit and conducted through an international network of researchers in the Gynaecologic Cancer InterGroup (GCIG).
ICON7 is an international, multicentre, randomised, open-label, Phase III study in 1,528 women with previously untreated epithelial ovarian, primary peritoneal or fallopian tube carcinoma. The trial evaluates Avastin plus standard of care chemotherapy (carboplatin and paclitaxel) followed by the continued use of Avastin alone, compared to chemotherapy alone.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.